Community Pharmacy England (CPE) has submitted evidence to Lord Darzi's investigation into NHS performance, highlighting the sector's value, challenges,
and potential opportunities.
Professor Ara Darzi, Baron Darzi of Denham, is leading the investigation, which has been commissioned by the Secretary of State for Health and Social Care to
examine the challenges facing the healthcare system ahead of the development of a new 10-year plan for health.
The investigation's findings are expected to be published in September 2024.
As the sector's representative body, CPE has provided evidence to ensure that the performance and challenges faced by community pharmacies are considered as
part of his review.
Their submission, based on internal analysis and independent reports, highlighted the severe funding crisis facing the sector, which is significantly impairing
access to care for those most in need.
Reacting to recommendations from a UK-first independent review, the Department of Health and Social Care (DHSC) has outlined action to tackle potential
bias in the design and use of medical devices.
Professor Dame Margaret Whitehead, professor of public health at the University of Liverpool, was appointed to lead the review, which focused on three
areas - optical devices such as pulse oximeters, AI-enabled devices, and polygenic risk scores (PRS) in genomics.
The DHSC commissioned the medical devices review after concerns were raised that pulse oximeters - widely used during the COVID-19 pandemic to monitor blood
oxygen levels - were not as accurate for patients with darker skin tones. There were worries that this could cause delays in treatment if dangerously low oxygen
levels in such patients were missed.
However, no evidence was found from NHS studies indicating that this differing performance had an impact on patient care.
Accepting the report's conclusions, the DHSC has committed to several actions, such as ensuring the safe use of pulse oximeter devices across a range of skin
tones within the NHS and eliminating racial bias from data sets employed in clinical studies.